SCHEDULE: Two Seas Capital Discloses 5% Stake in Esperion

Two Seas Capital LP and affiliates have disclosed a 5% beneficial ownership stake in Esperion Therapeutics, Inc. common stock.

Summary

• Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of 9,954,975 shares of Esperion Therapeutics, Inc. Common Stock.
• This ownership represents 5.0% of the issuer's outstanding Common Stock.
• The shares are held by Two Seas Global (Master) Fund LP, for which Two Seas Capital LP serves as investment manager.
• The percentage is calculated based on 198,199,462 shares of Common Stock outstanding as of May 1, 2025, as disclosed in Esperion's Form 10-Q filed on May 8, 2025.
• The Reporting Persons affirm that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Esperion Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a new significant institutional investor has taken a stake, which can be interpreted as a vote of confidence. However, the filing is purely factual and disclaims any intent to influence control, limiting the immediate impact beyond the ownership disclosure itself.

Positives

• A significant institutional investor, Two Seas Capital, has taken a 5% stake, potentially signaling confidence in Esperion Therapeutics, Inc.

Risks

• The filing explicitly states that the shares were not acquired for the purpose of changing or influencing the control of the issuer, which may limit the potential for activist-driven value creation.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Esperion Therapeutics, Inc. or the Reporting Persons regarding the issuer's future performance.

Industry Context

This filing indicates a new significant institutional investment in Esperion Therapeutics, Inc., a company operating in the biotechnology and pharmaceutical sector. Such investments can reflect investor interest in the company's drug pipeline, market position, or strategic direction within the competitive healthcare industry.

Stakeholder Impact

• Shareholders: The disclosure of a new 5% beneficial owner may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a new significant shareholder may influence future strategic considerations, though the filing states no intent to influence control.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant ownership stake by Two Seas Capital. While the acquisition of a 5% position by an institutional investor can be seen as a positive signal of confidence in Esperion Therapeutics, Inc., the filing itself does not provide new operational, financial, or strategic information about the company that would warrant a 'buy' or 'sell' recommendation. The investor explicitly states the shares were acquired in the ordinary course of business and not to influence control, suggesting a passive investment. Therefore, without additional fundamental analysis of Esperion's business, a 'hold' recommendation is appropriate, acknowledging the new institutional interest without overstating its immediate implications for the stock's intrinsic value.

Keywords

Esperion Therapeutics, Two Seas Capital, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Biotechnology, Pharmaceuticals